Spirulina and the Kallikrein-Kinin System

The Kallikrein-Kinin Cascade

Plasma kallikrein cleaves high-molecular-weight kininogen to release bradykinin (BK), a 9-amino-acid vasoactive peptide. Tissue kallikrein generates kallidin (Lys-BK) from low-MW kininogen. Both bradykinin and kallidin signal through B2R (constitutive) and B1R (induced by inflammation). Kininase II (= ACE) degrades bradykinin — connecting kallikrein-kinin to RAAS biology.

B2R: NO and Vasodilation

B2R is Gq-coupled, activating PLC-IP3-calcium signaling and eNOS in endothelial cells. The resulting NO drives vasodilation, increased vascular permeability, and anti-thrombotic effects. ACE inhibitors elevate bradykinin (since they also inhibit kininase II), contributing to their vasodilatory effects beyond Ang II reduction. Spirulina's ACE inhibition (covered separately) similarly elevates local bradykinin tone.

B1R: Inflammation Amplifier

B1R is induced by IL-1β, TNF-α, and LPS during inflammation. B1R-bradykinin signaling amplifies inflammation, pain, and vascular leak. Chronic B1R upregulation contributes to inflammatory pain and vascular dysfunction. Phycocyanin's reduced inflammation suppresses B1R induction by 20–30%, dampening this amplification loop.

ACE Inhibitor Cough

Bradykinin accumulation in the airways is the mechanism for ACE inhibitor-induced cough (a 10–20% side effect). Spirulina's milder ACE inhibition doesn't produce this signal at typical doses — perhaps because the magnitude of inhibition is lower or because parallel anti-inflammatory effects mitigate airway sensitization.

Cross-Talk with Complement

C1 inhibitor (covered separately as serpin) regulates both classical complement and kallikrein activation. C1-INH deficiency causes hereditary angioedema (bradykinin- mediated). The kallikrein-kinin and complement systems share inhibitors and substrates, making their regulation coordinated. Spirulina's effects on both systems are complementary.

Conclusion

Spirulina modulates the kallikrein-kinin system through ACE inhibition elevating local bradykinin tone (supporting endothelial NO production), reduced B1R induction via NF-κB suppression (20–30% decrease in inflammatory contexts), and parallel complement regulation. Clinical relevance spans cardiovascular effects beyond pure RAAS modulation, inflammatory pain modulation, and vascular permeability. The kallikrein-kinin system is less appreciated than RAAS but provides parallel vasoregulatory architecture engaged by spirulina's peptide and inflammation effects.